momenta
pharmaceuticals
announces
expiration
waiting
period
connection
proposed
sale
johnson
johnson
cambridge
globe
newswire
momenta
pharmaceuticals
nasdaq
mnta
momenta
company
biotechnology
company
focused
discovering
developing
novel
biologic
therapeutics
treat
rare
diseases
today
announced
expiration
waiting
period
antitrust
improvements
act
amended
hsr
connection
tender
offer
vigor
sub
vigor
wholly
owned
subsidiary
johnson
johnson
johnson
johnson
j
j
outstanding
shares
momenta
common
stock
per
share
offer
price
tender
offer
commenced
september
made
pursuant
previously
announced
merger
agreement
among
johnson
johnson
vigor
momenta
dated
august
merger
agreement
expiration
waiting
period
transaction
expected
close
early
october
subject
satisfaction
remaining
closing
conditions
set
forth
merger
agreement
unless
tender
offer
extended
tender
offer
expire
midnight
new
york
city
time
end
day
september
following
completion
tender
offer
johnson
johnson
expects
consummate
merger
momenta
vigor
soon
practicable
shares
momenta
tendered
tender
offer
acquired
johnson
johnson
converted
right
receive
offer
price
merger
agreement
unanimously
approved
boards
directors
momenta
johnson
johnson
includes
customary
termination
provisions
momenta
johnson
johnson
momenta
board
directors
unanimously
recommended
momenta
stockholders
tender
shares
pursuant
tender
offer
momenta
momenta
pharmaceuticals
biotechnology
company
validated
innovative
scientific
platform
focused
discovering
developing
novel
therapeutics
treat
rare
diseases
advancing
late
stage
biosimilar
portfolio
company
headquartered
cambridge
learn
momenta
please
visit
form
part
press
release
momenta
logo
trademarks
service
marks
property
momenta
pharmaceuticals
trade
names
trademarks
service
marks
property
respective
owners
statements
statements
press
release
regarding
management
future
expectations
beliefs
intentions
goals
strategies
plans
prospects
statements
within
meaning
private
securities
litigation
reform
act
including
limited
statements
timing
completion
tender
offer
transaction
product
development
goals
statements
may
identified
words
phrases
advance
anticipate
developed
believe
continue
expect
guidance
look
forward
may
plan
possible
potential
progress
propose
remains
target
working
toward
similar
words
expressions
negative
words
similar
words
expressions
statements
involve
known
unknown
risks
uncertainties
factors
including
uncertainties
timing
completion
tender
offer
subsequent
merger
ii
risk
tender
offer
subsequent
merger
may
completed
timely
manner
iii
uncertainties
percentage
momenta
stockholders
tendering
shares
tender
offer
iv
possibility
competing
offers
acquisition
proposals
momenta
made
v
possibility
various
conditions
consummation
tender
offer
subsequent
merger
may
satisfied
waived
vi
occurrence
event
change
circumstance
could
give
rise
termination
merger
agreement
among
johnson
johnson
vigor
momenta
including
circumstances
would
require
momenta
pay
termination
fee
vii
effect
announcement
pendency
transactions
contemplated
merger
agreement
momenta
ability
retain
hire
key
personnel
ability
maintain
relationships
customers
suppliers
others
business
operating
results
business
generally
viii
risks
related
diverting
management
attention
momenta
ongoing
business
operations
ix
risk
stockholder
litigation
connection
transactions
contemplated
merger
agreement
may
result
significant
costs
defense
indemnification
liability
x
referred
section
risk
factors
company
quarterly
report
form
period
ended
june
filed
securities
exchange
commission
well
documents
may
filed
company
time
time
securities
exchange
commission
result
risks
uncertainties
factors
company
actual
results
may
differ
materially
future
results
performance
achievements
discussed
implied
statements
contained
herein
company
providing
information
press
release
date
assumes
obligations
update
information
included
press
release
revise
statements
whether
result
new
information
future
events
otherwise
except
required
applicable
law
investor
contact
patty
eisenhaur
momenta
pharmaceuticals
ir
media
contact
karen
sharma
macdougall
ksharma
additional
information
find
communication
informational
purposes
offer
buy
solicitation
offer
sell
securities
momenta
solicitation
offer
buy
shares
momenta
common
stock
made
pursuant
tender
offer
statement
schedule
amended
including
offer
purchase
letter
transmittal
related
materials
johnson
johnson
vigor
filed
securities
exchange
commission
sec
addition
momenta
filed
sec
solicitation
recommendation
statement
schedule
amended
respect
tender
offer
investors
may
obtain
free
copy
materials
documents
filed
johnson
johnson
vigor
momenta
sec
website
maintained
sec
investors
may
also
obtain
charge
documents
filed
furnished
sec
momenta
investors
news
section
momenta
website
directing
request
momenta
investors
security
holders
advised
read
documents
including
solicitation
recommendation
statement
momenta
amendments
thereto
well
documents
relating
tender
offer
merger
filed
sec
carefully
entirety
prior
making
decisions
respect
whether
tender
shares
tender
offer
contain
important
information
including
terms
conditions
tender
offer
